Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 891-896

  Ansari, Jawaher ^a,b   Hussain, Syed Anwer ^a   Zarkar, Anjali ^a   Tanguay, Jacob S ^a   Bliss, Julie ^b   Glaholm, John ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chemotherapy; Docetaxel; Docetaxel re treatment; Hormone refractory disease; Prostate cancer; Second line chemotherapy; Third line chemotherapy

Indexed keywords

DOCETAXEL; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; FEASIBILITY STUDY; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RETREATMENT; SEPSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VISCERAL METASTASIS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 54949154102     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000088     Document Type: Article

References (21)

1. Cancer stats monograph 2004: Cancer incidence, survival and mortality in the UK and EU. Cancer Research UK, 2004.
2. Taylor CD, Elson P and Trump DL: Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11: 2167-2172, 1993.
3. Muthuramalingam SR, Patel K, Protheroe A: Management of patients with hormone refractory prostate cancer. Clin Oncol 16: 505-516, 2004.
4. Tannock IF, Osaba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisolone or prednisolone or prednisolone alone for symptomatic hormone resistant prostate cancer: a Canadian randomised trial with palliative end-point. J Clin Oncol 14: 1764-1765, 1996.
5. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
6. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and Estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N Engl J Med 351: 1515-1527, 2004.
7. National Institute for Health and Clinical Excellence: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. NICE technology appraisal guidance 101, June 2006 (www.nice.org.uk/TA101).
8. Rosenberg JE, Weinberg VK, Kelly WK, et al: Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 110: 556-563, 2007.
9. Nakabayashi M, Ling J, Xie W, et al: Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J 13: 125-129, 2007.
10. Ross RW, Beer TM, Jacobus S, et al: A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 11: 521-526, 2008.
11. Bubley GJ, Carducci M, Dahut W, et al: eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467, 1999.
12. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al: Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25: 3965-3970, 2007.
13. Petrylak DP, Ankerst DP, Jiang CS, et al: Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98: 516-521, 2006.
14. Cara S and Tannock IF: Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 12: 23-27, 2001.
15. Joshua AM, Nordman I, Venkataswaran R, et al: Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Intern Med J 35: 468-472, 2005.
16. Oh WK, Manola J, Babcic V, et al: Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 67: 1235-1240, 2006.
17. Michels J, Montemurro T, Murray N, et al: First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 106: 1041-1046, 2006.
18. Calais da Silva FM, Calais Da Silva F, Bono A, et al: Phase III intermittent MAB versus continuous MAB. J Clin Oncol 24: 220s, 2006.
19. Tunn UW, Eckart O, Kienle EF, et al: Can intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA relapse? First results of the randomized prospective phase III clinical trial EC-507. J Urol 169 (Suppl 4): 396a, 2003.
20. Beer TM, Garzotto M, Henner WD, et al: Multiple cycles of intermittent chemotherapy in Metastatic androgen-independent prostate cancer. Br J Cancer 91: 1425-1427, 2004.
21. Beer TM, Ryan CW, Venner PM, et al: Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112: 326-330, 2008.